MetLife Investment Management’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $311K | Buy |
34,106
+3,127
| +10% | +$28.5K | ﹤0.01% | 1937 |
|
|
2025
Q1 | $246K | Buy |
30,979
+5,343
| +21% | +$42.5K | ﹤0.01% | 2090 |
|
|
2024
Q4 | $139K | Sell |
25,636
-5,076
| -17% | -$27.6K | ﹤0.01% | 2474 |
|
|
2024
Q3 | $222K | Hold |
30,712
| – | – | ﹤0.01% | 2234 |
|
|
2024
Q2 | $334K | Buy |
30,712
+3,029
| +11% | +$32.9K | ﹤0.01% | 1945 |
|
|
2024
Q1 | $519K | Hold |
27,683
| – | – | ﹤0.01% | 1653 |
|
|
2023
Q4 | $600K | Hold |
27,683
| – | – | ﹤0.01% | 1582 |
|
|
2023
Q3 | $570K | Hold |
27,683
| – | – | ﹤0.01% | 1549 |
|
|
2023
Q2 | $1.3M | Buy |
27,683
+558
| +2% | +$26.2K | 0.01% | 1130 |
|
|
2023
Q1 | $1.14M | Hold |
27,125
| – | – | 0.01% | 1163 |
|
|
2022
Q4 | $1.03M | Hold |
27,125
| – | – | 0.01% | 1204 |
|
|
2022
Q3 | $1.06M | Hold |
27,125
| – | – | 0.01% | 1158 |
|
|
2022
Q2 | $876K | Buy |
27,125
+26,098
| +2,541% | +$843K | 0.01% | 1279 |
|
|
2022
Q1 | $34K | Buy |
+1,027
| New | +$34K | ﹤0.01% | 2689 |
|
|
2019
Q2 | – | Sell |
-67
| Closed | -$10.7K | – | 2566 |
|
|
2019
Q1 | $10.7K | Buy |
67
+5
| +8% | +$795 | ﹤0.01% | 2391 |
|
|
2018
Q4 | $5.94K | Sell |
62
-1
| -2% | -$96 | ﹤0.01% | 2445 |
|
|
2018
Q3 | $8.9K | Buy |
+63
| New | +$8.9K | ﹤0.01% | 2454 |
|
|
2018
Q2 | – | Sell |
-18,484
| Closed | -$2.98M | – | 2217 |
|
|
2018
Q1 | $2.98M | Buy |
18,484
+1,458
| +9% | +$235K | 0.04% | 617 |
|
|
2017
Q4 | $2.8M | Buy |
+17,026
| New | +$2.8M | 0.03% | 673 |
|